Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07336862 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bariatric Surgery Combined With GLP-1 Receptor Agonists Study

Study acronym: BS-GLP
StatusRecruiting
PhasePhase 1/2
Started2024-01-01
View on ClinicalTrials.gov ↗

Amendment history

2026-04-20
Study Status, Outcome Measures v2
Secondary endpoints28 to 22 entries
body fat percentage(BFP) Visceral fat area Muscle mass in kilograms Body fat percentage lean body mass (LBM) lean body mass percentage (LBMP)
2026-01-14
Study Status, Arms and Interventions, Outcome Measures v1
Secondary endpoints23 to 28 entries
body fat percentage(BFP) lean body mass (LBM) lean body mass percentage (LBMP) urine microalbumin-to-creatinine ratio (ACR) uric acid(UA)
2026-01-04
Original filing
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.
Trial Details
NCT Number NCT07336862
Lead Sponsor China-Japan Friendship Hospital
Conditions Obesity
Enrollment 200 participants
Start Date 2024-01-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-23